Figure 7.

SET9 regulates LNCaP cell proliferation, apoptosis and is aberrantly expressed in prostate cancer. (A) WST-1 proliferation assays were conducted in SET9-depleted and non-depleted LNCaP cells grown in steroid-depleted media supplemented with 10 nM DHT for 72 h. Data represents the mean of three independent experiments. (B) LNCaP cells grown in serum-containing media and transiently transfected with non-silencing (N/S), SET9 and/or p53 siRNAs were treated with and without 0.5 µM doxorubicin for 24-h prior to caspase 3 analysis. Data represents the mean of three independent repeats ± standard error (asterisk represents statistical significance <0.05). (C) Representative SET9 staining of prostate tissue using an anti-SET9 antibody in immunohistochemistry (left panel) and table summarizing nuclear and stromal staining pattern of SET9 in cancer and normal tissue (right panel).